Literature DB >> 3801287

Oxygen dependence for chemosensitization by misonidazole.

L Roizin-Towle, E J Hall, J P Pirro.   

Abstract

Misonidazole (MISO) potentiates the cell killing effect of certain chemotherapy agents, but only under hypoxic conditions. The purpose of the present study was to define the range of oxygen concentrations over which chemosensitization by MISO takes place using mammalian cells cultured in vitro, and to compare this with the oxygen levels required for radiosensitization. V-79 hamster cells, attached to permanox dishes, were gassed with known concentrations of oxygen (less than 10 to 200,000 ppm) and treated with 1 and 5 mM MISO for 4 h previous to exposure to the chemotherapy agent, melphalan. In a parallel series of experiments, under the same gassing conditions, cells were irradiated with graded doses of X-rays at various oxygen concentrations. The K factor i.e. the oxygen concentration which defined half the maximum effect was found to be approximately 4776 ppm for radiosensitization and approximately 400 ppm for chemosensitization by MISO. It is evident that a significantly more stringent level of hypoxia is required for chemosensitization by MISO to take place than for radiosensitization.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3801287      PMCID: PMC2001598          DOI: 10.1038/bjc.1986.262

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  A METHOD FOR DETERMINING DOSE-MODIFICATION FACTORS.

Authors:  M C PIKE; T ALPER
Journal:  Br J Radiol       Date:  1964-06       Impact factor: 3.039

2.  Effect of oxygen on misonidazole chemosensitization and cytotoxicity in vitro.

Authors:  R T Mulcahy
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

3.  Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole.

Authors:  J J Clement; M S Gorman; I Wodinsky; R Catane; R K Johnson
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

4.  Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo.

Authors:  A J Varghese; S Gulyas; J K Mohindra
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

5.  Selective enhancement of hypoxic cell killing by melphalan via thiol depletion: in vitro studies with hypoxic cell sensitizers and buthionine sulfoximine.

Authors:  L Roizin-Towle
Journal:  J Natl Cancer Inst       Date:  1985-01       Impact factor: 13.506

6.  Defense strategies against hypoxia and hypothermia.

Authors:  P W Hochachka
Journal:  Science       Date:  1986-01-17       Impact factor: 47.728

7.  Factors influencing the chemosensitization of melphalan by misonidazole.

Authors:  V S Randhawa; F A Stewart; J Denekamp; M R Stratford
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

8.  Studies with bleomycin and misonidazole on aerated and hypoxic cells.

Authors:  L Roizin-Towle; E J Hall
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

9.  Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.

Authors:  D W Siemann
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

10.  Enhanced cytotoxicity of antineoplastic agents following prolonged exposure to misonidazole.

Authors:  L A Roizin-Towle; E J Hall
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640

View more
  7 in total

1.  Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study.

Authors:  D J Stewart; R Goel; M C Cripps; S Huan; J Yau; S Verma
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  Nitroimidazoles for imaging hypoxic myocardium.

Authors:  H W Strauss; A Nunn; K Linder
Journal:  J Nucl Cardiol       Date:  1995 Sep-Oct       Impact factor: 5.952

Review 3.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

4.  Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.

Authors:  S E Brooks; T T Korbut; N P Dupuis; S A Holden; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 5.  Nitroimidazoles and imaging hypoxia.

Authors:  A Nunn; K Linder; H W Strauss
Journal:  Eur J Nucl Med       Date:  1995-03

6.  Combination of etanidazole with cyclophosphamide and platinum complexes.

Authors:  B A Teicher; T S Herman; L Shulman; G Bubley; C N Coleman; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Cytotoxic effect of misonidazole and cyclophosphamide on aerobic and hypoxic cells in a C3H mammary carcinoma in vivo.

Authors:  C Grau; S M Bentzen; J Overgaard
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.